

42255



1642  
PATENT

P#4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

McCormick et al.

Serial No. 10/067,893

Filed: 8 February 2002

For: Self Antigen Vaccines for Treating B Cell  
Lymphomas and Other Cancers

Patent Art Unit: 1642

Examiner: TBA

**RECEIVED**  
JUL 29 2002  
TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. § 1.97 and § 1.98, Applicants bring the disclosures listed on completed Forms PTO-1449 to the attention of the Examiner and request that the references be considered and made of record in the instant application. Copies of the references are attached.


Since the instant Information Disclosure Statement is being filed prior to issuance of a first Office Action on the merits, no certification under 37 C.F.R. §1.97(e) or fee under 37 C.F.R. §1.17(b) is required.

Applicants do not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the instant application.

Supplemental Information Disclosure Statement  
U.S. Ser. No.: 10/067,893

Prompt examination on the merits is requested respectfully.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Dean H. Nakamura', with a long horizontal flourish extending to the right.

Dean H. Nakamura

Reg. No. 33,981

Roylance, Abrams, Berdo & Goodman, L.L.P.  
1300 19<sup>th</sup> Street, N.W., Suite 600  
Washington, D.C. 20036  
(202) 659-9076

Dated: 26 July 2002

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/067,893
Filing Date	8 February 2002
First Named Inventor	MCCORMICK
Art Unit	1642
Examiner Name	TBA
Attorney Docket Number	42255

## **U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**RECEIVED**  
JUL 29 2002

TECH CENTER 1600/2900

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Country Code-Number- Kind Code (if known)				

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publishers, city and/or country where published	T
		LANGEVELD ET AL., Effective induction of neutralizing antibodies with the amino terminus of VP2 of canine parvovirus as a synthetic peptide, Vaccine, 1994, Volume 12, pp. 1473-1480.	
		FITCHEN ET AL., Plant virus expressing hybrid coat protein with added murine epitope elicits autoantibody response, Vaccine, 1995, Volume 13, pp. 1051 - 1057.	
		JERALA ET AL., Improved Expression and Evaluation of Polyethyleneimine Precipitation in Isolation of Recombinant Cysteine Proteinase Inhibitor Stefin B, Protein Expression and Purification, 1994, pp. 65 - 69.	

Examiner  
SignatureDate  
Considered

